



SARS-CoV2 Spike RBD K417N, N501Y mutant

Datasheet, Version 2/2016

protean
On the bow of top biotechnology

Catalog #	2106
Synonyms	RBD
Type	Recombinant
Source	E. coli
Species	SARS-CoV2
Tag	His6
Form	Liquid
Purity	>95% by SDS PAGE
Shipping	Ice pack

Introduction

Recombinant SARS-CoV-2 RBD domain with C-terminal His-tag, expressed into periplasm of E. coli.

Description

The spike (S) glycoprotein of coronaviruses mediates binding and entry of the virus into the host cell. The S protein is also a major immunogen and a target for development of antiviral drugs. The spike protein is a transmembrane protein composed of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain (RBD) responsible for binding to the receptor angiotensin-converting enzyme 2 (ACE2). Several mutants of the spike protein has been identified so far with various affinity to ACE2 and changed immunogenicity.

Application

ELISA, Western blot, LIA, Protein arrays

Purification method

Affinity chromatography.

Formulation

500 ug/mL, 10mM Tris pH 7.5, 50mM KCl

Specificity

RBD domain of the Spike protein (AA 319-541) from original Wuhan-Hu-1 isolate (NC_045512). The N501Y mutation is characteristic for all three of the currently observed fast spreading SARS-CoV-2 virus variants B.1.1.7, B.1.351 and P1. The mutation K417N is characteristic for the fast spreading SARS-CoV-2 virus variant B.1.351 emerged in South Africa.

Storage

-80C. Aliquot upon arrival.

Analyte specific reagent (ASR) manufactured under ISO 13485.

Country of origin: Czech Republic

